KIRA PHARMACEUTICALS
Kira Pharmaceuticals their treatment gives pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases.
KIRA PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2017-01-01
Address:
Hong Kong, Hong Kong Island, Hong Kong
Country:
Hong Kong
Website Url:
http://www.kirapharma.com
Total Employee:
11+
Status:
Active
Total Funding:
99.5 M USD
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
TauRx Pharmaceuticals
TauRx Pharmaceuticals is a life sciences company developing drugs and diagnostics for neurodegenerative diseases.
Current Advisors List
Board_member
Current Employees Featured
Wenru Song President & Head of R&D, Co-founder @ Kira Pharmaceuticals
President & Head of R&D, Co-founder
2017-01-01
Gonghua Pan Co-Founder, and Head of China Operations @ Kira Pharmaceuticals
Co-Founder, and Head of China Operations
2020-05-01
Frederick Beddingfield Chief Executive Officer @ Kira Pharmaceuticals
Chief Executive Officer
2020-05-01
Teri loxam COO & CFO @ Kira Pharmaceuticals
COO & CFO
2021-11-01
Founder
Investors List
Foresite Capital
Foresite Capital investment in Series B - Kira Pharmaceuticals
APlus Partners
APlus Partners investment in Series B - Kira Pharmaceuticals
Vivo Capital
Vivo Capital investment in Series B - Kira Pharmaceuticals
RA Capital Management
RA Capital Management investment in Series B - Kira Pharmaceuticals
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series B - Kira Pharmaceuticals
Quan Capital
Quan Capital investment in Series B - Kira Pharmaceuticals
Sinopharm Capital
Sinopharm Capital investment in Venture Round - Kira Pharmaceuticals
Quan Capital
Quan Capital investment in Venture Round - Kira Pharmaceuticals
6 Dimensions Capital
6 Dimensions Capital investment in Venture Round - Kira Pharmaceuticals
Qiming Venture Partners
Qiming Venture Partners investment in Venture Round - Kira Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.kirapharma.com
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kira Pharmaceuticals"
About Us - Kira Pharma
About Our Team. Kira’s experienced team includes established drug developers and protein engineers, world-renowned experts in complement biology and leaders from across the pharma and biotech industry.See details»
Kira Homepage
Kira Pharmaceuticals is a clinical-stage biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement …See details»
Kira Pharmaceuticals - Crunchbase Company Profile & Funding
Kira Pharmaceuticals is a Biotechnology Research Company. View contacts for Kira Pharmaceuticals to access new leads and connect with decision-makers.See details»
Kira Pharmaceuticals - LinkedIn
Kira Pharmaceuticals is a clinical-stage, global biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline ...See details»
Kira Pharma Company Profile 2024: Valuation, Funding ... - PitchBook
Kira Pharma General Information Description. Developer of antibody drugs designed to offer transformative therapies for patients with complement-mediated diseases. The company …See details»
KP104, the first bifunctional biologic in complement - Kira Pharma
Our lead program, KP104, represents a significant breakthrough in complement therapy. It is a potent, first-in-class bifunctional biologic designed to simultaneously and selectively block the …See details»
Kira Pharmaceuticals - Craft
Kira Pharmaceuticals has 5 employees across 2 locations and $99.5 m in total funding,. See insights on Kira Pharmaceuticals including office locations, competitors, revenue, financials, …See details»
Kira Pharmaceuticals Expands Executive Leadership Team with …
Feb 23, 2021 CAMBRIDGE, Mass. and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of …See details»
Kira Pharmaceuticals Receives FDA Orphan Drug ... - Markets Insider
Jul 28, 2022 KP104 has completed a Phase 1 first-in-human (FIH) study and is entering Phase 2 trials across multiple indications. The Phase 1 clinical trial was a randomized, double blind, …See details»
Kira Pharmaceuticals Presents Complete Data from Phase 1 …
Nov 3, 2022 Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today presented complete first-in …See details»
News and Press Releases - Kira Pharma
May 16, 2024 CAMBRIDGE, MA (January 5, 2023) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune …See details»
Kira Pharmaceuticals - Work in biotech
Kira Pharmaceuticals is pioneering complement-targeted therapies to treat immune-mediated diseases. The complement system is a complex with an abundance of proteins involved, but it …See details»
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing …
Jan 7, 2021 CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of …See details»
Kira Pharmaceuticals Receives FDA Orphan Drug Designation for …
Jul 28, 2022 CAMBRIDGE, Mass. and SUZHOU, China, July 28, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational …See details»
Kira Pharmaceuticals to Present Positive Long-term Results of …
May 16, 2024 Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced …See details»
Science - Kira Pharma
"At Kira, our mission is urgent. We can't wait because our patients can't wait for life-enhancing and life-saving therapies, so we’re working tirelessly on their behalf."See details»
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for ...
Nov 12, 2020 CAMBRIDGE, Md. and SUZHOU, China, Nov. 12, 2020 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of …See details»
Our Pipeline - Kira Pharma
KP301 is a long-acting mAb against a clinically validated target prominent in neutrophilic and other autoimmune inflammatory disorders.See details»
Presentations
Aug 26, 2022 See our latest presentations and posters. EMCHD 2022: Design and characterization of KP104, a bifunctional anti-C5 mAb and FH1-5 fusion protein that …See details»
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 ...
Feb 2, 2021 CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Feb. 2, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of …See details»